Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 3, 2015, Pages 92-102

  Hinnen, Deborah ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

dapagliflozin; diabetes; glucose; kidney; SGLT2 inhibitors

Indexed keywords

ALBUMIN; CREATININE; DAPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; MAGNESIUM; METFORMIN; PHOSPHATE; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN;

ADD ON THERAPY; BODY WEIGHT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIARRHEA; DISEASE DURATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART DEATH; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGURIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RENAL PROTECTION; REVIEW; RHINOPHARYNGITIS; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84930580133     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018815575273     Document Type: Review

References (52)

1. American Diabetes Association (2014) Standards of medical care in diabetes–2014. Diabetes Care 37: S14–S80.
2. Bailey C. Gross J. Hennicken D. Iqbal N. Mansfield T. List J. (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11: 43.
3. Bailey C. Gross J. Pieters A. Bastien A. List J. (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223–2233.
4. Bakris G. Fonseca V. Sharma K. Wright E. (2009) Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 75: 1272–1277.
5. Barnett A. Mithal A. Manassie J. Jones R. Rattunde H. Woerle H. et al. (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 369–384.
6. Bays H. (2013) Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther 4: 195–220.
7. Benfield T. Jensen J. Nordestgaard B. (2007) Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 50: 549–554.
8. Bolinder J. Ljunggren O. Johansson L. Wilding J. Langkilde A. Sjostrom C. et al. (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16: 159–169.
9. Bolinder J. Ljunggren O. Kullberg J. Johansson L. Wilding J. Langkilde A. et al. (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97: 1020–1031.
10. Bristol-Myers Squibb and AstraZeneca (2014) Farxiga® (dapagliflozin). Full prescribing information. Princeton, NJ, and Wilmington, DE: Bristol-Myers Squibb and AstraZeneca.
11. Cefalu W. Leiter L. Yoon K. Arias P. Niskanen L. Xie J. et al. (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941–950.
12. Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention.
13. Centers for Disease Control and Prevention (2014) National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention.
14. de Leon E. Jacober S. Sobel J. Foxman B. (2002) Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2: 1.
15. de Fronzo R. Hompesch M. Kasichayanula S. Liu X. Hong Y. Pfister M. et al. (2013) Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36: 3169–3176.
16. Ferrannini E. Ramos S. Salsali A. Tang W. List J. (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33: 2217–2224.
17. Fonseca V. (2009) Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32: S151–S156.
18. Food and Drug Administration (2008) Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Center for Drug Evaluation and Research.
19. Food and Drug Administration (2013) FDA briefing document. NDA 202293. Dapagliflozin oral tablets, 5 and 10 mg. Advisory Committee Meeting, 12 December 2013.
20. Freeman J. (2013) Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Postgrad Med 125: 214–226.
21. Garber A. Abrahamson M. Barzilay J. Blonde L. Bloomgarden Z. Bush M. et al. (2013) American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement–executive summary. Endocr Pract 19: 536–557.
22. Geerlings S. Fonseca V. Castro-Diaz D. List J. Parikh S. (2014) Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 103: 373–381.
23. Häring H. Merker L. Seewaldt-Becker E. Weimer M. Meinicke T. Woerle H. et al. (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36: 3396–3404.
24. Heerspink H. Holtkamp F. de Zeeuw D. Ravid M. (2011) Monitoring kidney function and albuminuria in patients with diabetes. Diabetes Care 34(Suppl. 2): S325–S329.
25. Henry R. Murray A. Marmolejo M. Hennicken D. Ptaszynska A. List J. (2012) Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66: 446–456.
26. International Diabetes Federation (2012) Global guideline for type 2 diabetes. Brussels: International Diabetes Federation. Available at: http://www.idf.org/new-global-guideline-type-2-diabetes-out-now-0 (Accessed 27 October 2014).
27. International Diabetes Federation (2013) IDF atlas, 6th edn. Brussels: International Diabetes Federation. Available at: http://www.idf.org/diabetesatlas (accessed 27 October 2014).
28. Inzucchi S. Bergenstal R. Buse J. Diamant M. Ferrannini E. Nauck M. et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364–1379.
29. Jabbour S. Hardy E. Sugg J. Parikh S. and Study 10 Group (2014) Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37: 740–750.
30. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013 a) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 479–484.
31. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013 b) Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 473–478.
32. Kasichayanula S. Chang M. Liu X. Shyu W. Griffen S. Lacreta F. et al. (2012) Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther 29: 163–177.
33. Kasichayanula S. Liu X. Shyu W. Zhang W. Pfister M. Griffen S. et al. (2011) Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13: 47–54.
34. Kohan D. Fioretto P. Tang W. List J. (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962–971.
35. Lambers Heerspink H. de Zeeuw D. Wie L. Leslie B. List J. (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15: 853–862.
36. List J. Whaley J. (2011) Glucose dynamics and mechanistic implications of SGLT 2 inhibitors in animals and humans. Kidney Int 79: S20–S27.
37. Matthaei S. Rohwedder K. Grohl A. Johnsson E. (2013) Dapagliflozin improves glycaemic control and reduces body weight as add-on therapy to metformin plus sulphonylurea. Presented at European Association for the Study of Diabetes, Barcelona, Spain.
38. Nauck M. Del Prato S. Meier J. Duran-Garcia S. Rohwedder K. Elze M. et al. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34: 2015–2022.
39. Nicolle L. Capuano G. Fung A. Usiskin K. (2014) Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 126: 7–17.
40. Nyirjesy P. Zhao Y. Ways K. Usiskin K. (2012) Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 28: 1173–1178.
41. Ptaszynska A. Johnsson K. Parikh S. de Bruin T. Apanovitch A. List J. (2014) Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf 37: 815–829.
42. Rosenstock J. Vico M. Wei L. Salsali A. List J. (2012) Effects of dapagliflozin, an SGLT 2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35: 1473–1478.
43. Rosenstock J. Hansen L. Zee P. Li Y. Cook W. Hirshberg B. Iqbal N. (2015) Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38: 376–383.
44. Stark Casagrande S. Fradkin J. Saydah S. Rust K. Cowie C. (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 36: 2271–2279.
45. Strojek K. Yoon K. Hruba V. Elze M. Langkilde A. Parikh S. (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13: 928–938.
46. Vasilakou D. Karagiannis T. Athanasiadou E. Mainou M. Liakos A. Bekiari E. et al. (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159: 262–274.
47. Weber M. Mansfield T. Alessi F. Ptaszynska A. (2013 a) Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker. Circulation 128: abstract A13144.
48. Weber M. Mansfield T. T'joen C. Ptaszynska A. (2013 b) Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen. Circulation 128: abstract A13165.
49. Wilding J. Woo V. Rohwedder K. Sugg J. Parikh S. (2014) Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over two years. Diabetes Obes Metab 16: 124–136.
50. Wilding J. Woo V. Soler N. Pahor A. Sugg J. Rohwedder K. et al. (2012) Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med 156: 405–415.
51. Yale J. Bakris G. Cariou B. Yue D. David-Neto E. Xi L. et al. (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15: 463–473.
52. Zhang L. Feng Y. List J. Kasichayanula S. Pfister M. (2010) Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 12: 510–516.